Diagnostic imaging of pheochromocytoma

Frontiers of Hormone Research

Volumn 31, Issue , 2004, Pages 107-120

  Pacak, Karel ^a   Eisenhofer, Graeme ^b   Ilias, Ioannis ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 56249106544     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (55)

1. Pacak K, Chrousos GP, Koch CA, Lenders JW, Eisenhofer G: Pheochromocytoma: Progress in diagnosis, therapy, and genetics; in Margioris A, Chrousos GP (eds): Adrenal Disorders. Totowa, Humana Press, 2001, pp 479-523.
2. Plouin PF, Gimenez-Roqueplo AP, La Batide Alanore A, Salenave S, Duclos JM: Progrès recents dans le diagnostic, l'évaluation pronostique et le traitement des pheochromocytomes. Rev Med Interne 2000;21:1075-1085.
3. Klinger HC, Klinger PJ, Martin JK, Smallridge RC, Smith SL, Hinder RA: Pheochromocytoma. Urology 2001;57:1025-1032.
4. Gooding GA: Adrenal, pancreatic, and scrotal ultrasound in endocrine disease. Radiol Clin North Am 1993;31:1069-1083.
5. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS: Recent advances in genetics, diagnosis, localization and treatment of pheochromocytoma. Ann Intern Med 2001;134:315-329.
6. Quint LE, Glazer GM, Francis IR, Shapiro B, Chenevert TL: Pheochromocytoma and paraganglioma: Comparison of MR imaging with CT and I-131 MIBG scintigraphy. Radiology 1987;165:89-93.
7. Ling D, Lee JKT: The adrenals; in Lee JKT, Sagel SS, Stanley RJ (eds): Computed Body Tomography with MRI Correlation, ed 2. New York, Raven Press, 1989, pp 827-849.
8. Dacie JE, White FE: Radiology of endocrine disease; in Besser GM, Thorner MO (eds): Atlas of Endocrine Imaging. London, Wolfe, 1993, pp 1-78.
9. Goldstein RE, O'Neil JA Jr, Holcomb GW 3rd, Morgan WM 3rd, Neblett WW 3rd, Oates JA, Brown N, Nadeau J, Smith B, Page DL, Abumrad NN, Scott HW Jr: Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999;229:755-766.
10. Francis IR, Korobkin M: Pheochromocytoma. Radiol Clin North Am 1996;34:1101-1112.
11. Mannelli M, Ianni L, Cilotti A, Conti A: Pheochromocytoma in Italy: A multicentric retrospective study. Eur J Endocrinol 1999;141:619-624.
12. Maurea S, Cuocolo A, Reynolds JC, Neumann RD, Salvatore M: Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison. Q J Nucl Med 1996;40:365-371.
13. Pacak K, Goldstein DS, Doppman JL, Shulkin BL, Udelsman R, Eisenhofer G: A 'pheo' lurks: Novel approaches for locating occult pheochromocytoma. J Clin Endocrinol Metab 2001;86:3641-3646.
14. Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, Norton JA, Walther MM, Keiser HR, Neumann RD: Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: Comparison with CT and MRI. J Nucl Med 1993;34:173-179.
15. Schmedtje JF Jr, Sax S, Pool JL, Goldfarb RA, Nelson EB: Localization of ectopic pheochromocytomas by magnetic resonance imaging. Am J Med 1987;83:770-772.
16. Chang A, Glazer HS, Lee JKT, Ling D, Heiken JP: Adrenal gland: MRI imaging. Radiology 1987;163:123-128.
17. Mayo-Smith WW, Boland GW, Noto RB, Lee MJ: State-of-the-art adrenal imaging. Radiographics 2001;21:995-1012.
18. Shapiro B, Gross MD, Shulkin B: Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab 2001;12:469-475.
19. Mozley PD, Kim CK, Moshin J, Gosfield E, Alavi A: The efficacy of iodine-123-MIBG as a screening test for pheochromocytoma. J Nucl Med 1994;35:1138-1144.
20. Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, Tobes MC, Beierwaltes WH, Thompson NW: Scintigraphic localization of pheochromocytoma. N Engl J Med 1981;305:12-17.
21. Lynn MD, Shapiro B, Sisson JC, Beierwaltes WH, Meyers LJ, Ackerman R, Mangner TJ: Pheochromocytoma and the normal adrenal medulla: Improved visualization with I-123 MIBG scintigraphy. Radiology 1985;155:789-792.
22. Fujita A, Hyodoh H, Kawamura Y, Kanegae K, Furuse M, Kanazawa K: Use of fusion images of I-131 metaiodobenzylguanidine, SPECT and magnetic resonance studies to identify a malignant pheochromocytoma. Clin Nucl Med 2000;25:440-442.
23. Sisson JC, Shulkin BL: Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999;43:217-223.
24. Tsuchimochi S, Nakajo M, Nakabeppu Y, Tani A: Metastatic pulmonary pheochromocytomas: Positive I-123 MIBG SPECT with negative I-131 MIBG and equivocal I-123 MIBG planar imaging. Clin Nucl Med 1997;22:687-690.
25. Shulkin BL, Shapiro B, Francis IR, Dorr R, Shen SW, Sisson JC: Primary extra-adrenal pheochromocytoma: Positive I-123 MIBG imaging with negative I-131 MIBG imaging. Clin Nucl Med 1986;11:851-854.
26. van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP, Bosman FT, Kwekkeboom DJ: [(123)I] metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:685-693.
27. Nguyen HH, Proye CA, Carnaille B, Combemale F, Pattou FN, Huglo D: Tumour size: The only predictive factor for 131I MIBG uptake in phaechromocytoma and paraganglioma. Aust NZ J Surg 1999;69:350-353.
28. Whalen RK, Althausen AF, Daniels GH: Extra-adrenal pheochromocytoma. J Urol 1992;147:1-10.
29. Bravo EL: Evolving concepts in the pathophysiology, diagnosis and treatment of pheochromocytoma. Endocr Rev 1994;15:356-358.
30. Furuta N, Kiyota H, Yoshigoe F, Hasegawa N, Ohishi Y: Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol 1999;6:119-124.
31. Eisenhofer G, Pacak K, Goldstein DS, Chen C, Shulkin B: 123I-MIBG scintigraphy of catecholamine systems: Impediments to applications in clinical medicine. Eur J Nucl Med 2000;27:611-612.
32. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC: Pheochromocytomas: Imaging with 2-[fluorine-18]fluoro-2-deoxy-d-glucose PET. Radiology 1999;212:35-41.
33. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS, Rosenspire KC, Shapiro B, Sisson JC, Kuhl DE: PET scanning with hydroxyephedrine: An approach to the localization of pheochromocytoma. J Nucl Med 1992;33:1125-1131.
34. Shulkin BL, Wienland DM, Shapiro B, Sisson JC: PET epinephrine studies of pheochromocytoma. J Nucl Med 1995;36:229P.
35. 18F DOPA whole-body PET - Initial results. Radiology 2002;222:507-512.
36. Hovevey-Sion D, Eisenhofer G, Kopin IJ, Kirk KL, Chang PC, Szemeredi K, Goldstein DS: Metabolic fate of injected radiolabelled dopamine and 2-fluorodopamine in rats. Neuropharmacology 1990;29:881-887.
37. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS: 6-[18F]-fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001;38:6-8.
38. Ilias I, Yu J, Goldstein D, Eisenhofer G, Chen C, Carrasquillo J, Padmanabhan H, Perera S, Pacak K: 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the evaluation of patients with pheochromocytoma (abstract P3-511). Proceedings of the 84th Annual Meeting of the Endocrine Society, San Francisco, 2002, p 611.
39. Krenning EP, Kwekkeboom DJ, Pawels S, Kvols LK, Reubi JC: Somatostatin receptor scintigraphy; in Freeman LM (ed): Nuclear Medicine Annual 1995. New York, Raven Press, 1995, pp 242-244.
40. Lamberts SW, Krenning EP, Reubi JC: The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991;12:450-482.
41. Krenning EP, Kwekkekeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC: Somatostatin receptor scintigraphy with [111In-DTPA-DPhe1]and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-731.
42. Lauriero F, Rubini G, D'Addabo F, Rubini D, Schettini F, D'Addabo A: I-131 MIBG scintig raphy of neuroectodermal tumors. Comparison between I-131 MIBG and In-DTPA-octreotide. Clin Nucl Med 1995;20:243-249.
43. Reubi JC, Wasser B, Khoshla S, Kvols L, Krenning E, Lamberts S: In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 1992;74:1082-1089.
44. Limouris GS, Giannakopoulos V, Stavraka A, Toubanakis N, Vlahos L: Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 MIBG scintimaging in neural crest tumors. Anticancer Res 1997;17:1589-1592.
45. Kopf D, Bockisch A, Steinert H, Hahn K, Beyer J, Neumann HP, Hensen J, Lehnert H: Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clin Endocrinol 1997;46:39-44.
46. Lastoria S, Maurea S, Vergara E, Acampa W, Varrella P, Klain M, Muto P, Bernardy JD, Salvatore M: Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors. Q J Nucl Med 1995;39:S145-S149.
47. Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B, Parmentier C: Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 1995;36:1-6.
48. Hoefnagel CA: Metaiodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumors. Eur J Nucl Med 1994;21:561-581.
49. Maurea S, Lastoria S, Caraco C, Klain M, Varrella P, Acampa W, Muto P, Salvatore M: The role or radiolabeled somatostatin analogs in adrenal imaging. Nucl Med Biol 1996;23:677-680.
50. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R, Britton KE, Grossman AB: Comparison of somatostatin analog and metaiodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001;86:895-902.
51. Behr TM, Behe M, Becker W: Diagnostic applications of radiolabeled peptides in nuclear endocrinology. Q J Nucl Med 1999;43:268-280.
52. L ynn MD, Braunstein EM, Wahl RL, Shapiro B, Gross MD, Rabbani R: Bone metastases in pheochromocytoma: Comparative studies of efficacy of imaging. Radiology 1986;160:701-706.
53. Rubello D, Bui C, Casara D, Gross MD, Fig LM, Shapiro B: Functional scintigraphy of the adrenal gland. Eur J Endocrinol 2002;147:13-28.
54. Virgolini I, Traub T, Leimer M, Novotny C, Pagerl T, Ofluoglou S, Halvadjieva E, Smith-Jones P, Flores J, Li SR, Angelberger P, Havlik E, Andreae F, Raderer M, Kurtatran A, Niederle B, Dudczak R: New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q J Nucl Med 2000;44:50-58.
55. Clerc J, Mardon K, Galoons H, Loc'h C, Lumbroso J, Merlet P, Zhu J, Jeusset J, Syrota A, Fragu P: Assessing intratumor distribution and uptake with MIBG versus MIBG imaging and targeting xenografted PC-12 pheochromocytoma cell line. J Nucl Med 1995;36:859-866.